Walleye Capital
CLDX icon

Walleye Capital’s Celldex Therapeutics CLDX Stock Holding History

Walleye Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258K Buy
+8,147
New +$222K ﹤0.01% 3167
2025
Q2 		– Sell
-93,327
Closed -$1.69M – 4561
2025
Q1 		$1.69M Buy
+93,327
New +$2.09M 0.01% 1540
2024
Q3 		– Sell
-50,183
Closed -$1.86M – 5361
2024
Q2 		$1.86M Buy
50,183
+49,147
+4,744% +$1.85M ﹤0.01% 2181
2024
Q1 		$43.5K Sell
1,036
-168,232
-99% -$6.91M ﹤0.01% 4729
2023
Q4 		$6.71M Buy
169,268
+10,275
+6% +$302K 0.01% 920
2023
Q3 		$4.38M Buy
158,993
+37,741
+31% +$1.18M 0.01% 1127
2023
Q2 		$4.11M Buy
121,252
+51,436
+74% +$1.73M 0.01% 858
2023
Q1 		$2.51M Sell
69,816
-15,456
-18% -$667K 0.04% 600
2022
Q4 		$3.8M Sell
85,272
-86,630
-50% -$3.09M 0.07% 334
2022
Q3 		$4.83M Buy
+171,902
New +$5.27M 0.09% 239
2022
Q2 		– Sell
-37,381
Closed -$1.27M – 2403
2022
Q1 		$1.27M Buy
37,381
+23,154
+163% +$740K 0.03% 522
2021
Q4 		$550K Buy
+14,227
New +$620K 0.02% 929

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Walleye Capital's CLDX Position: Q1 2026 in Review

Walleye Capital opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 8,147 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #3167 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CLDX as recently as Q1 2025.

Walleye Capital first reported a position in CLDX in Q4 2021 and has held it in 12 quarters since. The position peaked at $6.71M in Q4 2023. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Walleye Capital held 8,147 shares of Celldex Therapeutics worth $258K as of Q1 2026.
  • Celldex Therapeutics was a new Walleye Capital position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3167 holding.
  • Walleye Capital first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Walleye Capital's Celldex Therapeutics position peaked at $6.71M in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.